| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Apr 2025 | 8 Apr 2025 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 inter alia to consider and approve the audited standalone and consolidated financial results for the quarter and year ending March 31 2025; and to consider the recommendation of final dividend if any. Outcome of the Board Meeting - April 23, 2025. (As Per BSE Announcement Dated on:23.04.2025) | ||
| Board Meeting | 23 Jan 2025 | 13 Jan 2025 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ending December 31 2024 amongst other routine matters. Outcome of the Board Meeting - January 23, 2025 (As Per BSE Announcement Dated on: 23/01/2025) | ||
| Board Meeting | 23 Oct 2024 | 4 Oct 2024 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ending September 30 2024 amongst other routine matters. Outcome of the Board Meeting - October 23, 2024. (As Per BSE Announcement dated on 23.10.2024) | ||
| Board Meeting | 24 Jul 2024 | 28 Jun 2024 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter ending June 30 2024 amongst other routine matters Outcome of the Board Meeting - July 24, 2024. (As per BSE Announcement Dated on 24/07/2024) | ||
The outcome of the inspection has been classified as “Voluntary Action Indicated” or VAI.
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
